Reuters Health Report

Click to View in Browser 04/10/2014 Health workers in Guinea's capital to hunt for Ebola cases GENEVA (Reuters) - Health workers will fan out in Guinea's capital of Conakry to try to identify people who may have been exposed to the deadly Ebola virus, the World Health Organisation (WHO) said on Thursday. Natco moves to oppose Gilead hepatitis C drug patent in India: source MUMBAI (Reuters) - India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's breakthrough hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. Lion dies in Hungary zoo from anthrax-infected meat BUDAPEST (Reuters) - A lion in a Hungarian zoo died after it ate beef infected with the deadly anthrax disease identified in a nearby farm in the eastern region of the country, national news agency MTI reported on Thursday. Biogen's blood disorder drug succeeds in late-stage trial (Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial. French plan to push copycat biotech drugs worries Big Pharma PARIS (Reuters) - France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany. Bristol-Myers hepatitis C treatment cures up to 90 percent: study (Reuters) - A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday. Stockpiles of Roche Tamiflu drug are waste of money, review finds LONDON (Reuters) - Researchers who have fought for years to get full data on Roche's flu medicine Tamiflu said on Thursday that governments who stockpile it are wasting billions of dollars on a drug whose effectiveness is in doubt. Merck hepatitis C drugs shine in easier to treat patients: study (Reuters) - A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field. Exclusive: Heart docs seek curbs on kidney-zapping hypertension devices (Reuters) - Several leading U.S. and European heart doctors are calling for curbs, or even a moratorium, on using devices meant to lower blood pressure by zapping kidney arteries, following a surprising failure of the technology in a clinical trial. Data trove shows U.S. doctors reap millions from Medicare NEW YORK (Reuters) - In 2012, south Florida ophthalmologist Salomon Melgen received $20.8 million in Medicare payments, the highest amount the government health plan for the elderly and disabled paid an individual provider that year, according to a Reuters analysis of federal data released on Wednesday. Related Video Cherry Blossom season in Washington Communities clean up after storms in the South The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend